# CJC-1295 / Research — Mechanism, trials, detection, and the published evidence graph > The primary research record on CJC-1295: GHRH-receptor mechanism, Phase 1 pharmacokinetics, the terminated Phase 2 program, preserved GH pulsatility, and the analytical-chemistry literature driven by anti-doping detection. Twenty findings across mechanism, Phase 1 pharmacokinetics, preserved pulsatility, the terminated Phase 2 program, and the analytical literature. ## What the literature says, in brief The published record on CJC-1295 is small and tractable. Its core is two Phase 1 trials in healthy adults — both from 2006 — that established the pharmacokinetics, documented GH and IGF-1 elevations, and showed that normal pulsatile GH secretion is preserved under sustained GHRH-analog stimulation [2][3]. A single preclinical paper rescued growth-deficient mice with once-daily dosing [4]. A Phase 2 program in HIV-associated visceral fat was discontinued without completing its endpoints [11]. Around that clinical core sits an analytical literature driven largely by anti-doping authorities: immunoaffinity screens, LC-MS/MS confirmatory methods, and more recent antibody-free urinary assays, all needed because the albumin-conjugated circulating form of CJC-1295 defeats standard peptide detection workflows [6][7][8][9]. A 2024 FDA advisory committee reviewed the compound and cited safety and immunogenicity concerns when it declined to recommend it for the 503A compounding list [22]. The research page below renders each of these findings as a node in a connected graph. Mechanism feeds into pharmacokinetics, which feeds into trial design, which feeds into the regulatory status, which feeds into the detection literature. Edges matter here as much as nodes. ## Mechanism — GHRH-receptor agonism on a long carrier CJC-1295 binds the growth-hormone-releasing-hormone receptor (GHRH-R), a class B G-protein-coupled receptor expressed on anterior-pituitary somatotrophs. Receptor occupancy activates Gs alpha, which couples to adenylyl cyclase, raises intracellular cyclic AMP, activates protein kinase A, and phosphorylates CREB — the canonical cAMP/PKA/CREB cascade. Downstream of CREB, Pit-1 transcription rises, GH gene transcription is induced, and stored GH is released by exocytosis from somatotroph secretory granules [15]. Secondary signaling through MAPK/ERK and calcium/calmodulin pathways mediates somatotroph proliferation, which is why GHRH-knockout mice receiving once-daily CJC-1295 show somatotroph hyperplasia alongside normalized GH/IGF-1 output [4] [15]. The mechanistic distinction between CJC-1295 and earlier GHRH analogs is not the receptor binding — it is the residence time on the receptor's substrate pool. Free GHRH(1-29) is cleared from plasma in minutes by DPP-4 and renal filtration. CJC-1295, covalently linked to albumin Cys34 via its maleimide handle, is preserved across days [1] [2] [16]. The pituitary thus sees a continuously replenished ligand pool rather than a brief bolus. ## Pharmacokinetics — the 5.8 to 8.1 day half-life The pivotal Phase 1 trial (Teichman 2006) administered single subcutaneous CJC-1295 doses of 30, 60, 125, and 250 microgram per kilogram to healthy adult volunteers, then multiple-dose 60 microgram per kilogram weekly for 28 to 49 days [2]. Plasma GH rose two- to tenfold and remained elevated for six or more days after a single dose. IGF-1 rose 1.5- to threefold and remained elevated for nine to eleven days. The estimated plasma half-life was 5.8 to 8.1 days. With weekly dosing, cumulative IGF-1 elevation lasted approximately 28 days [2]. The half-life is the dominant pharmacokinetic feature of the compound. Within the broader GHRH-analog class, native sermorelin clears with a plasma half-life of roughly 11 to 12 minutes; modified GRF(1-29) without DAC has a half-life of about 30 minutes; tesamorelin clears in about 26 to 38 minutes; CJC-1295 with DAC sits at 5.8 to 8.1 days [16]. The DAC modification places this single analog roughly ten thousand-fold above its parent peptide on the kinetic ladder, and that single fact governs everything downstream — dosing intervals, IGF-1 exposure duration, the irreversibility of a dose once given, and the difficulty of mass-spectrometric detection. ## Preserved pulsatility — Ionescu and Frohman, 2006 A concern with any sustained GHRH agonist is desensitization. Continuous ligand exposure can downregulate receptors, exhaust secretory granules, or flatten the natural pulsatile rhythm of GH secretion — and GH pulsatility appears to matter biologically. The Ionescu and Frohman 2006 study addressed this directly. Healthy men aged 20 to 40 received a single 60 or 90 microgram per kilogram subcutaneous CJC-1295 dose. One week later, the investigators sampled GH every ten minutes over twelve overnight hours [3]. The finding: pulsatility was preserved. GH pulse frequency and amplitude were unchanged versus baseline. What changed was the trough — basal GH between pulses rose 7.5-fold — and the integrated exposure: total GH secretion over twelve hours rose 46 percent, and IGF-1 measured the following morning was 45 percent higher than baseline [3]. The continuous albumin-tethered stimulation produced by CJC-1295 raised the floor without flattening the curve. ## Preclinical — GHRH-knockout mouse rescue The Alba 2006 paper provides the cleanest preclinical demonstration of CJC-1295 activity. GHRH-knockout mice are a genetic model of severe growth-hormone deficiency: they fail to thrive, with reduced body weight, body length, femur length, tibia length, and pituitary GH mRNA. Once-daily subcutaneous CJC-1295 at two microgram per animal for five weeks normalized all of these endpoints [4]. Every-48-hour and every-72-hour dosing produced partial normalization, supporting a daily-equivalent biological window of activity despite the multi-day plasma half-life. The Alba data also documented somatotroph hyperplasia — increased pituitary RNA and GH mRNA content — consistent with the MAPK/ERK proliferative arm of GHRH-R signaling [4] [15]. This is mechanistically expected for sustained GHRH-R agonism but is a finding that has not been characterized at scale in human cohorts. ## The terminated Phase 2 — NCT00267527 ConjuChem Biotechnologies, the original developer, ran a single Phase 2 program in CJC-1295's clinical history. NCT00267527 was a multicenter, randomized, double-blind, placebo-controlled trial enrolling 192 HIV-positive adults with visceral lipodystrophy [11]. Subjects received once-weekly subcutaneous CJC-1295 in escalating low-dose (60 / 90 / 120 microgram per kilogram) or high-dose (60 / 120 / 240 microgram per kilogram) cohorts, or placebo, for twelve weeks. The trial was halted after a participant cardiac death two hours after the eleventh weekly dose. The attending physician adjudicated the event as related to pre-existing coronary artery disease and unrelated to study drug. The body-composition endpoints — the primary measures the trial was designed to read — were never published in peer-reviewed literature [11]. No further sponsor-led trials have been registered. No regulatory submission was filed. The Phase 2 termination is the severed edge in the CJC-1295 development graph: the trial program advanced through discovery and Phase 1, attempted Phase 2 in a single indication, and stopped. ## Detection methodology — the analytical literature Mass-spectrometric detection of intact CJC-1295 in blood is intrinsically difficult. Once injected, the peptide rapidly conjugates not only to albumin Cys34 but also to a heterogeneous mixture of other plasma thiols — free cysteine, glutathione, and other thiol-bearing proteins. The apparent molecular weight of circulating species therefore varies across each individual sample, defeating standard top-down peptide identification workflows [12]. Bottom-up tryptic-digest workflows (release a signature peptide from albumin) and antibody-based capture are the only reliable detection strategies. The analytical literature reflects this constraint. Timms 2019 (drug testing in thoroughbred racing) developed an immuno-polymerase chain reaction (I-PCR) assay using paired monoclonal antibodies that detects the CJC-1295-albumin conjugate in equine plasma down to 0.8 pg/mL, with a practical screening threshold set at 50 pg/mL [6]. A companion paper from the same group describes an orthogonal LC-MS/MS confirmation method using immunoaffinity capture followed by tryptic digestion, reaching identification at approximately 180 pg/mL in 1 mL of plasma [7]. The pair — I-PCR screen plus LC-MS/MS confirmation — is the operational toolchain for racing-jurisdiction detection. Knoop 2016 extended the immunoaffinity-LC-HRMS/MS approach to human plasma for CJC-1295 alongside sermorelin, modified GRF(1-29), and tesamorelin, with a limit of detection below 50 pg/mL [8]. A notable observation: sermorelin yields a GRF(3-29) cleavage metabolite within thirty minutes of administration, while CJC-1295's D-Ala-2 substitution blocks the same cleavage, and intact CJC-1295 remains detectable in rat plasma for at least eight hours [8]. Knoop 2022 then demonstrated an antibody-free ultrafiltration-based nanoLC-HRMS/MS method for urinary detection of GHRH analogs including CJC-1295 at limits of detection of 5 to 25 pg/mL — a meaningful simplification of routine anti-doping screening because it removes the cost and reproducibility issues of immunoaffinity sample preparation [9]. Earlier in the timeline, Henninge 2010 reported the forensic identification of CJC-1295 in an unknown pharmaceutical preparation seized by Norwegian authorities in 2009 — the first documented confirmation of gray-market CJC-1295 supply outside legitimate clinical-trial channels [10]. ## Adverse events documented in the Phase 1 program The published Phase 1 data describe injection-site reactions (transient pain, swelling, induration, occasional local urticaria) as the most frequently reported adverse event, generally mild and short-lived [2] [14]. Pharmacological doses produced dose-dependent water retention and joint stiffness consistent with sustained GH/IGF-1 elevation [14]. No serious drug-related adverse events were reported at doses up to and including 60 microgram per kilogram [2] [14]. The single cardiac death in the Phase 2 program was adjudicated as drug-unrelated [11]. A broader consideration sits outside the Phase 1 dataset. Epidemiologic data consistently associate chronically elevated IGF-1 with modestly higher risk of certain cancers (prostate, breast, colorectal) [17]. The 1.5- to threefold IGF-1 elevations observed for nine to twenty-eight days following CJC-1295 dosing have not been studied against cancer-incidence endpoints, and no causal link between CJC-1295 and human carcinogenesis has been demonstrated [17]. The concern is mechanistic and unresolved, not empirically established for this compound. ## Regulatory and anti-doping status CJC-1295 has never received marketing authorization from FDA, EMA, MHRA, TGA, PMDA, or any other regulatory authority for any indication. The compound is a research chemical in regulatory terms. The World Anti-Doping Agency lists CJC-1295 by name under Section S2 of the WADA Prohibited List — peptide hormones, growth factors, related substances, and mimetics, subsection 2.3 (GHRH and its analogs and mimetics) — and the compound is prohibited at all times, both in-competition and out-of-competition. Athletes subject to WADA jurisdiction are subject to sanction if CJC-1295 is detected in plasma or urine samples by any of the methods described in the analytical literature above [6] [7] [8] [9]. Recent biomarker work (Esposito 2009) characterized the serum protein profile of CJC-1295-treated subjects via two-dimensional gel electrophoresis and identified five candidate protein spots that change after a single dose, including a candidate biomarker linearly correlated with IGF-1 levels [5]. The biomarker work feeds back into the analytical chain — if intact CJC-1295 is hard to detect, the indirect fingerprint of GH/IGF-1 axis activation may itself be informative for athlete-passport-style longitudinal monitoring. --- An editorial summary of peer-reviewed findings — not a clinical recommendation, not a vendor, not a node in any supply graph.